The nine-valent HPV vaccine is suitable for ages 9-45. The nine-valent human papillomavirus (HPV) vaccine, which is used to prevent HPV infections, protects against nine subtypes of the virus, HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, and the vaccine is available for ages 9-45. The risk of exposure to HPV increases with age, especially with the onset of sexual activity, so it is recommended that age-eligible women receive the vaccine as early as possible. The HPV vaccine is a prophylactic vaccine that does not cure existing HPV infections and related diseases, does not prevent all HPV types of infections, and does not stop HPV infections from progressing to disease progression. Therefore, regular cervical cancer screening is still needed after HPV vaccination. Women who are pregnant or preparing for pregnancy should delay vaccination until the end of pregnancy, and breastfeeding women should exercise caution when receiving the vaccine. HPV vaccination is contraindicated in persons who have hypersensitivity to the active ingredient of the vaccine or to any of the excipient components, and persons who have symptoms of hypersensitivity after injection of the product should not be revaccinated with the product.